Bioequivalence and Safety Evaluation of Imatinib mesylate Tablets in Patients of Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Abstract

The current study was designed to characterize the pharmacokinetic profile and to assess newlinebioequivalence of the sponsor s Test formulation (Imatinib mesylate 400 mg tablets) with newlineReference Listed product (Gleevec® 400 mg tablets, Novartis Pharmaceuticals) under newlineFed conditions, in adult patients of Philadelphia chromosome positive Chronic Myeloid newlineLeukemia (Ph+ CML) stabilized on Imatinib mesylate 400 mg. In addition, study was newlineaimed to monitor safety profile of Investigational Medicinal Products (IMPs). newlineit The study has concluded that Test product Imatinib mesylate 400mg tablets newlinemanufactured for Ranbaxy Laboratories Limited, India is bioequivalent and safe, and can be used interchangeably in clinical practice. newline

Description

Keywords

Citation

item.page.endorsement

item.page.review

item.page.supplemented

item.page.referenced